Compare CDIO & SNOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CDIO | SNOA |
|---|---|---|
| Founded | 2017 | 1999 |
| Country | United States | United States |
| Employees | 17 | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0M | 6.1M |
| IPO Year | N/A | 2006 |
| Metric | CDIO | SNOA |
|---|---|---|
| Price | $2.05 | $2.31 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 262.6K | 25.1K |
| Earning Date | 05-14-2026 | 02-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $14,288,000.00 |
| Revenue This Year | $171,906.75 | $23.00 |
| Revenue Next Year | N/A | $24.59 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 12.19 |
| 52 Week Low | $0.18 | $1.98 |
| 52 Week High | $7.91 | $6.92 |
| Indicator | CDIO | SNOA |
|---|---|---|
| Relative Strength Index (RSI) | 38.77 | 44.92 |
| Support Level | $1.65 | $2.30 |
| Resistance Level | $2.03 | $2.54 |
| Average True Range (ATR) | 0.23 | 0.17 |
| MACD | -0.02 | 0.03 |
| Stochastic Oscillator | 27.45 | 55.36 |
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases and associated comorbidities by leveraging its Artificial Intelligence (AI)-driven Multi-Omics Engine. The company has developed two clinical products: Epi+Gen CHD and PrecisionCHD, epigenetics-based clinical blood tests capable of assessing risk for a coronary heart disease (CHD) event, including heart attacks. Additionally, its portfolio includes HeartRisk, a cardiovascular disease risk intelligence platform, and CardioInnovate360, a research-use-only solution launched to support the discovery, development, and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases.
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.